KR880012224A - Substituted 1,3-dioxolane and 1,3-dioxane derivatives, preparation method and use thereof - Google Patents

Substituted 1,3-dioxolane and 1,3-dioxane derivatives, preparation method and use thereof Download PDF

Info

Publication number
KR880012224A
KR880012224A KR1019880003491A KR880003491A KR880012224A KR 880012224 A KR880012224 A KR 880012224A KR 1019880003491 A KR1019880003491 A KR 1019880003491A KR 880003491 A KR880003491 A KR 880003491A KR 880012224 A KR880012224 A KR 880012224A
Authority
KR
South Korea
Prior art keywords
tolyl
compound
dioxolane
pharmaceutical composition
formula
Prior art date
Application number
KR1019880003491A
Other languages
Korean (ko)
Inventor
네델슨 제프리
Original Assignee
진 크라머 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 진 크라머 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 진 크라머 한스 루돌프 하우스
Publication of KR880012224A publication Critical patent/KR880012224A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음No content

Description

치환된 I,3-디옥솔란 및 I,3-디옥산 유도체, 이의 제조방법 및 용도Substituted I, 3-dioxolane and I, 3-dioxane Derivatives, Methods for Making and Uses thereof

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (12)

약학적으로 허용되는 희석제 또는 담체와 함께, 다음 일반식(I) 화합물을 함유함을 특징으로 하는 약학적 조성물.A pharmaceutical composition comprising the following general formula (I) compound together with a pharmaceutically acceptable diluent or carrier: 상기식에서 m은 1 또는 2이고, n은 1 또는 2이며, R1은 Wherein m is 1 or 2, n is 1 or 2, and R 1 is (여기에서, p는 0 내지 4이고, g는 1 내지 4이다), -C(C2H5)3또는 아다만틸이고, R2는 수소 메틸 페닐 또는 벤질이며, 톨일 치환체의 메틸 그룹은 메타 또는 파라 위치에 존재한다. Wherein p is 0 to 4 and g is 1 to 4, -C (C 2 H 5 ) 3 or adamantyl, R 2 is hydrogen methyl phenyl or benzyl, and the methyl group of the tolyl substituent is Present in meta or para position. 제 1항에 있어서, 경구투여용 약학적 조성물 또는 비경구 멸균 약학적 조성물이 약학적 조성물.The pharmaceutical composition of claim 1, wherein the pharmaceutical composition for oral administration or parenteral sterile pharmaceutical composition is a pharmaceutical composition. 제 2항에 있어서, 정제, 분산성, 산제, 과립제, 캅셀제, 시럽, 엘릭서 또는 멸균 유제 형태인 약학적 조성물.A pharmaceutical composition according to claim 2 in the form of a tablet, dispersible, powder, granule, capsule, syrup, elixir or sterile emulsion. 당뇨병 치료를 필요로 하는 환자에게 당뇨병 치료적 유효량의 제 1항에 정의된 일반식(I) 화합물 투여함을 특징으로 하는 당뇨병 치료방법.A method for treating diabetes, comprising administering to a patient in need thereof a therapeutically effective amount of the general formula (I) compound as defined in claim 1. 약제로서 사용하기 위한 제 1항에 정의된 일반식(I) 화합물.A compound of formula (I) as defined in claim 1 for use as a medicament. 당뇨병 치료제로서 사용하기 위한 제 1항에 정의된 일반식(I) 화합물.A compound of formula (I) as defined in claim 1 for use as a diabetes treatment. 당뇨병 치료용 약제를 제조하기 위한 제 1항에 정의된 일반식(I) 화합물.A compound of formula (I) as defined in claim 1 for the preparation of a medicament for the treatment of diabetes. 화합물이 2-(t-부틸)-2-(P-톨일)-1,3-디옥솔라인, 제 1항 내지 제 3항중 어느 한 항에 따른 약학적조성물, 제 4항에 따른 방법, 또는 제 5항 내지 7항중 어느 한 항에 따른 용도.The compound is 2- (t-butyl) -2- (P-tolyl) -1,3-dioxoline, a pharmaceutical composition according to any one of claims 1 to 3, a method according to claim 4, or Use according to any one of claims 5 to 7. n이 1이고, R2는 수소이며, 톨일 치환체의 메틸 그룹이 파라 위치에 존재하는 경우 R1은 t-부틸이 아닌, 제 1항에 정의된 일반식(I) 화합물.A compound of formula (I) as defined in claim 1, wherein n is 1, R 2 is hydrogen and the methyl group of the tolyl substituent is present in the para position R 1 is not t-butyl. 제 9항에 있어서, 2-(1,1-디메틸부틸)-2-(P-톨일)-1,3-디옥솔란;2-(1-메틸사이클로헥실)-2-(P-톨일)-1,3-디옥솔란;2-(1-메틸사이클로프로필)-2-(P-톨일)-1,3-디옥솔란;2-(1,1-디메틸프로필)-2-(P-톨일)-1,3-디옥솔란;2-아다만틸2--(P-톨일)-1,3-디옥솔란;2-(1,1-디에틸프로필)-2-(P-톨일)-1,3-디옥솔란;2-(t-부틸)-2-(m-톨일)-1,3-디옥솔란;2-(t-부틸)-2-(P-톨일)-5,5-디메틸-1,3-디옥산;2-(t-부틸)-2-(P-톨일)1,3-디옥산;2-(t-부틸)-2-(p-톨일)-4,5-디메틸-1,3-디옥솔란 ; 및 2-(t-부틸)-2-(P-톨일)-4-메틸-1,3-디옥솔란중에서 선택된 하합물.A 2- (1,1-dimethylbutyl) -2- (P-tolyl) -1,3-dioxolane; 2- (1-methylcyclohexyl) -2- (P-tolyl)- 1,3-dioxolane; 2- (1-methylcyclopropyl) -2- (P-tolyl) -1,3-dioxolane; 2- (1,1-dimethylpropyl) -2- (P-tolyl) -1,3-dioxolane; 2-adamantyl2-(P-tolyl) -1,3-dioxolane; 2- (1,1-diethylpropyl) -2- (P-tolyl) -1 , 3-dioxolane; 2- (t-butyl) -2- (m-tolyl) -1,3-dioxolane; 2- (t-butyl) -2- (P-tolyl) -5,5-dimethyl -1,3-dioxane; 2- (t-butyl) -2- (P-tolyl) 1,3-dioxane; 2- (t-butyl) -2- (p-tolyl) -4,5- Dimethyl-1,3-dioxolane; And a mixture selected from 2- (t-butyl) -2- (P-tolyl) -4-methyl-1,3-dioxolane. 일반식(II)의 화합물을 일반식(III)의 화합물과 반응시킴을 특징으로 하여 제 9항에 따른 화합물을 제조하는 방법.A process for preparing a compound according to claim 9 characterized by reacting a compound of formula (II) with a compound of formula (III). 상기식에서, m, n, R1및 R2는 제 9항에서 정의한 바와 같다.Wherein m, n, R 1 and R 2 are as defined in claim 9. 제 1항에서 정의된 일반식(I) 화합물을 약학적으로 허용되는 희석제 또는 담체와 화합물을 특징으로하여 제 1 항에 다른 약학적 조성물을 제조하는 방법.A process for preparing a pharmaceutical composition according to claim 1, characterized in that the compound of formula (I) as defined in claim 1 is characterized by a pharmaceutically acceptable diluent or carrier. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019880003491A 1987-04-01 1988-03-30 Substituted 1,3-dioxolane and 1,3-dioxane derivatives, preparation method and use thereof KR880012224A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3411887A 1987-04-01 1987-04-01
US34118 1987-04-01

Publications (1)

Publication Number Publication Date
KR880012224A true KR880012224A (en) 1988-11-26

Family

ID=21874422

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880003491A KR880012224A (en) 1987-04-01 1988-03-30 Substituted 1,3-dioxolane and 1,3-dioxane derivatives, preparation method and use thereof

Country Status (18)

Country Link
JP (1) JPS63277672A (en)
KR (1) KR880012224A (en)
AU (1) AU1400788A (en)
BE (1) BE1000783A3 (en)
DE (1) DE3810874A1 (en)
DK (1) DK179288A (en)
ES (1) ES2011831A6 (en)
FR (1) FR2613226B1 (en)
GB (1) GB2202849A (en)
GR (1) GR880100196A (en)
HU (1) HUT50156A (en)
IL (1) IL85920A0 (en)
IT (1) IT1219895B (en)
LU (1) LU87176A1 (en)
NL (1) NL8800805A (en)
PT (1) PT87127B (en)
SE (1) SE8801166L (en)
ZA (1) ZA882350B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8701961D0 (en) * 1987-01-29 1987-03-04 Unilever Plc Perfumery materials

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3235589A1 (en) * 1982-09-25 1984-03-29 Hoechst Ag, 6230 Frankfurt BENZYL ETHER FROM PHENOL-MANNICH-BASEN, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS, INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
DK179288D0 (en) 1988-03-30
GR880100196A (en) 1989-01-31
IL85920A0 (en) 1988-09-30
DK179288A (en) 1988-10-02
GB2202849A (en) 1988-10-05
GB8807503D0 (en) 1988-05-05
BE1000783A3 (en) 1989-04-04
LU87176A1 (en) 1988-11-17
NL8800805A (en) 1988-11-01
SE8801166L (en) 1988-10-02
AU1400788A (en) 1988-10-06
FR2613226A1 (en) 1988-10-07
ZA882350B (en) 1989-12-27
IT1219895B (en) 1990-05-24
IT8847797A0 (en) 1988-03-30
HUT50156A (en) 1989-12-28
PT87127B (en) 1992-07-31
PT87127A (en) 1988-04-01
SE8801166D0 (en) 1988-03-29
DE3810874A1 (en) 1988-10-20
JPS63277672A (en) 1988-11-15
FR2613226B1 (en) 1989-09-15
ES2011831A6 (en) 1990-02-16

Similar Documents

Publication Publication Date Title
KR900006341A (en) Heterocyclic compounds
KR970705393A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
HUP9802630A2 (en) Chiral methyl phenyl oxazolidinones, process for their preparation, use thereof and pharmaceutical compositions containing them
KR920000774A (en) Interstitial medicine
JPS5513275A (en) Prodrug of non-steroid anti-inflammatory drug having improved absorption and anti-inflammatory drug composition comprising it
DK157482A (en) GALENIC PREPARATION CONTAINING GALLOPAMIL OR VERAPAMIL AND PROCEDURES FOR PREPARING IT
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR940702491A (en) Oxazolidone derivatives
KR880012224A (en) Substituted 1,3-dioxolane and 1,3-dioxane derivatives, preparation method and use thereof
DE69217613D1 (en) Bicyclic derivatives containing nitrogen, processes for their preparation and pharmaceutical preparations containing them
KR927003537A (en) 4,5-cycloalkano-3-benzeazin-7-ol derivatives and uses thereof
KR890012942A (en) 5-substituted ornithine derivatives
KR890701526A (en) Keratosis Drug
KR890014109A (en) Medication
KR970704723A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents (DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS)
KR880004810A (en) Peptic Ulcer Treatment
KR900001665A (en) Cycloalkylthiazole derivatives
KR880012577A (en) Thiadiazole guanidine compound and preparation method thereof
GB1508338A (en) Pharmaceutical compositions
KR900701273A (en) Anti-Ecstatic Ergoline Derivatives
KR950700063A (en) Brofaromine as an agent for treating post-traumatic stress
US3666859A (en) 3,4-dicarbethoxy-{62 -phenethylcarbamic acid, ethyl ester in treating depression
US3092551A (en) Medication for psychic disturbances
KR940007010A (en) Oxazolidine
KR950704322A (en) Spirofuranone Derivatives and Their Use in the Treatment of Neurodegenerative Disorders

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid